The serum interleukin-18 is a potential marker for development of post-stroke depression

Neurological Research

Volumn 32, Issue 4, 2010, Pages 340-346

  Yang, Lingli ^a   Zhang, Zhijun ^a   Sun, Dingming ^a   Xu, Zhi ^a   Zhang, Xiangrong ^a   Li, Lingjiang ^b  

^a SOUTHEAST UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Biomarker; Interleukin 18; Post stroke depression

Indexed keywords

INTERLEUKIN 18; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD LEVEL; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MEASUREMENT; MONTGOMERY ASBERG DEPRESSION RATING SCALE; POST STROKE DEPRESSION; SCHOOL ADMISSION; SCREENING; SYMPTOMATOLOGY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COMORBIDITY; DEPRESSIVE DISORDER; FEMALE; HUMANS; INTERLEUKIN-18; INTERLEUKIN-6; MALE; MIDDLE AGED; PREVALENCE; STROKE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77952208050     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164110X12656393665080     Document Type: Article

References (49)

1. Smith RS. The macrophage theory of depression. Med Hypotheses 1991; 35: 298-306
2. Dantzer R, O'Connor JC, Freund GG, et al. From inflammation to sickness and depression: When the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46-56
3. Maes M, Meltzer HY, Bosmans E, et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 1995; 34: 301-309
4. Pollak Y, Ovadia H, Goshen I, et al. Behavioral aspects of experimental autoimmune encephalomyelitis. J Neuroimmunol 2000; 104: 31-36
5. Reichenberg A, Yirmiya R, Schuld A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001; 58: 445-452
6. Brydon L, Harrison NA, Walker C, et al. Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans. Biol Psychiatry 2008; 63: 1022-1029
7. Connor TJ, Leonard BE. Depression, stress and immunological activation: The role of cytokines in depressive disorders. Life Sci 1998; 62: 583-606
8. Tiemeier H, Hofman A, van Tuijl HR, et al. Inflammatory proteins and depression in the elderly. Epidemiology 2003; 14: 103-107
9. Tuglu C, Kara SH, Caliyurt O, et al. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) 2003; 170: 429-433
10. Brambilla F, Maggioni M. Blood levels of cytokines in elderly patients with major depressive disorder. Acta Psychiatr Scand 1998; 97: 309-313
11. Haack M, Hinze-Selch D, Fenzel T, et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: Effects of confounding factors and diagnosis. J Psychiatr Res 1999; 33: 407-418
12. Appels A, Bar FW, Bar J, et al. Inflammation, depressive symptomatology, and coronary artery disease. Psychosom Med 2000; 62: 601-605
13. Miller GE, Stetler CA, Carney RM, et al. Clinical depression and inflammatory risk markers for coronary heart disease. Am J Cardiol 2002; 90: 1279-1283
14. Okamura H, Tsutsi H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995; 378: 88-91
15. Conti B, Park LC, Calingasan NY, et al. Cultures of astrocytes and microglia express interleukin 18. Brain Res Mol Brain Res 1999; 67: 46-52
16. Ushio S, Namba M, Okura T, et al. Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol 1996; 156: 4274-4279
17. Kohno K, Kurimoto M. Interleukin 18, a cytokine which resembles IL-1 structurally and IL-12 functionally but exerts its effect independently of both. Clin Immunol Immunopathol 1998; 86: 11-15
18. Tsutsui H, Nakanishi K, Matsui K, et al. IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J Immunol 1996; 157: 3967-3973
19. Curran B, O'Connor JJ. The pro-inflammatory cytokine interleukin-18 impairs long-term potentiation and NMDA receptormediated transmission in the rat hippocampus in vitro. Neuroscience 2001; 108: 83-90
20. Merendino RA, Di Rosa AE, Di Pasquale G, et al. Interleukin-18 and CD30 serum levels in patients with moderate-severe depression. Mediators Inflamm 2002; 11: 265-267
21. Kokai M, Kashiwamura S, Okamura H, et al. Plasma interleukin-18 levels in patients with psychiatric disorders. J Immunother 2002; 25 (Suppl. 1): S68-S71
22. Wang X, Yue TL, Young PR, et al. Expression of interleukin-6, cfos, and zif268 mRNAs in rat ischemic cortex. J Cereb Blood Flow Metab 1995; 15: 166-171
23. Jander S, Schroeter M, Stoll G. Role of NMDA receptor signaling in the regulation of inflammatory gene expression after focal brain ischemia. J Neuroimmunol 2000; 109: 181-187
24. Jander S, Schroeter M, Stoll G. Interleukin-18 expression after focal ischemia of the rat brain: Association with the late-stage inflammatory response. J Cereb Blood Flow Metab 2002; 22: 62-70
25. Waje-Andreassen U, Krakenes J, Ulvestad E, et al. IL-6: An early marker for outcome in acute ischemic stroke. Acta Neurol Scand 2005; 111: 360-365
26. Mazzotta G, Sarchielli P, Caso V, et al. Different cytokine levels in thrombolysis patients as predictors for clinical outcome. Eur J Neurol 2004; 11: 377-381
27. Zaremba J, Losy J. Early TNF-alpha levels correlate with ischaemic stroke severity. Acta Neurol Scand 2001; 104: 288-295
28. Zaremba J, Losy J. Interleukin-18 in acute ischaemic stroke patients. Neurol Sci 2003; 24: 117-124
29. Yuen CM, Chiu CA, Chang LT, et al. Level and value of interleukin-18 after acute ischemic stroke. Circ J 2007; 71: 1691-1696
30. Spalletta G, Bossu P, Ciaramella A, et al. The etiology of poststroke depression: A review of the literature and a new hypothesis involving inflammatory cytokines. Mol Psychiatry 2006; 11: 984-991
31. Adams HP Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24(1), 35-41.
32. Caeiro L, Ferro JM, Santos CO, et al. Depression in acute stroke. J Psychiatry Neurosci 2006; 31: 377-383
33. Hackett ML, Yapa C, Parag V, et al. Frequency of depression after stroke: A systematic review of observational studies. Stroke 2005; 36: 1330-1340
34. Townend BS, Whyte S, Desborough T, et al. Longitudinal prevalence and determinants of early mood disorder post-stroke. J Clin Neurosci 2007; 14: 429-434
35. Hackett ML, Anderson CS. Predictors of depression after stroke: A systematic review of observational studies. Stroke 2005; 36: 2296-2301
36. Hoptman MJ, Gunning-Dixon FM, Murphy CF, et al. Blood pressure and white matter integrity in geriatric depression. J Affect Disord 2009; 115: 171-176
37. Fassbender K, Rossol S, Kammer T, et al. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: Kinetics of secretion and relation to the extent of brain damage and outcome of disease. J Neurol Sci 1994; 122: 135-139
38. Sanchez-Moreno C, Dashe JF, Scott T, et al. Decreased levels of plasma vitamin C and increased concentrations of inflammatory and oxidative stress markers after stroke. Stroke 2004; 35: 163-168
39. Schins A, Tulner D, Lousberg R, et al. Inflammatory markers in depressed post-myocardial infarction patients. J Psychiatr Res. 2005; 39: 137-144
40. Hedtjarn M, Leverin AL, Eriksson K, et al. Interleukin-18 involvement in hypoxic-ischemic brain injury. J Neurosci 2002; 22: 5910-5919
41. Pomerantz BJ, Reznikov LL, Harken AH, et al. Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc Natl Acad Sci USA 2001; 98: 2871-2876
42. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 201-217
43. Liebau C, Baltzer AW, Schmidt S, et al. Interleukin-12 and interleukin-18 induce indoleamine 2,3-dioxygenase (IDO) activity in human osteosarcoma cell lines independently from interferongamma. Anticancer Res 2002; 22: 931-936
44. Maes M, Verkerk R, Bonaccorso S, et al. Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation. Life Sci 2002; 71: 1837-1848
45. Wichers MC, Maes M. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J Psychiatry Neurosci 2004; 29: 11-17
46. Matsuyama T, Hata R, Yamamoto Y, et al. Localization of Fas antigen mRNA induced in postischemic murine forebrain by in situ hybridization. Brain Res Mol Brain Res 1995; 34: 166-172
47. Mallat Z, Henry P, Fressonnet R, et al. Increased plasma concentrations of interleukin-18 in acute coronary syndromes. Heart 2002; 88: 467-469
48. Yamaoka-Tojo M, Tojo T, Inomata T, et al. Circulating levels of interleukin 18 reflect etiologies of heart failure: Th1/Th2 cytokine imbalance exaggerates the pathophysiology of advanced heart failure. J Card Fail 2002; 8: 21-27
49. Blankenberg S, Tiret L, Bickel C, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002; 106: 24-30